[1]张 璇,朱海龙,哈敏文△.TGFβSMAD通路基因多态性与鼻咽癌预后相关性研究[J].陕西医学杂志,2019,(11):1430-1434.
点击复制

TGFβSMAD通路基因多态性与鼻咽癌预后相关性研究
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
期数:
2019年11期
页码:
1430-1434
栏目:
基础研究
出版日期:
2019-11-05

文章信息/Info

文章编号:
DOI:10.3969/j.issn.10007377.2019.11.006
作者:
张 璇; 朱海龙; 哈敏文△
锦州医科大学附属第一医院肿瘤科（锦州 121000）
关键词:
鼻咽癌; 单核苷酸多态性; 预后; 无远处转移生存; 转化生长因子β信号通路; 相关性
分类号:
R739.62
文献标志码:
A
摘要:
摘 要 目的:探讨TGFβSMAD信号通路中关键基因的SNP位点基因型与鼻咽癌患者预后间的关联性。方法：以296例鼻咽癌患者为研究对象，通过采用Sequenom Mass ARRAY 法对样本进行SNP的基因分型并分析TGFβ信号通路中主要基因的12个SNP位点基因型与鼻咽癌患者预后的关联性。结果:296例受试者进行随访发现，其3年无远处转移生存率以及总生存率分别为8480%（251例）、9155%（271例）。3年无远处转移生存率单因素分析结果显示，TGFβ1基因rs1800469、rs1800470位点CC基因型携带者低于、高于CT/TT基因型携带者（P＜005）；SMAD4基因rs12958604位点AA基因型携带者高于AG/GG基因型携带者（P＜005）。3年无远处转移风险多因素分析结果显示，TGFβ1基因rs1800469、rs1800470位点TC/TT基因型携带者约为CC基因型携带者的0541、2322倍；SMAD4基因rs12958604位点AG/GG基因型携带者约为AA基因型携带者的2357倍（P＜005）。另外TGFβ1基因rs1800469位点CT/TT基因型携带者3年总生存率高于CC基因型携带者（P＜005），但3年死亡风险约为CC基因型携带者的0455倍（P＜005）。同时携带三种、两种“不利”基因型的鼻咽癌患者3年远处转移风险分别为不携带“不利”基因型患者的5937倍、2469倍。结论：鼻咽癌患者中，TGFβ1基因rs1800469位点CC 基因型、rs1800470位点TT基因型以及SMAD4基因rs12598604位点AG/GG型携带者3年远处转移风险高，TGFβ1基因rs1800469位点CC基因型携带者3年总生存率低。

参考文献/References:

[1] Qiu WZ,Peng XS,Xia HQ,et al. A retrospective study comparing the outcomes and toxicities of intensitymodulated radiotherapy versus twodimensional conventional radiotherapy for the treatment of children and adolescent nasopharyngeal carcinoma[J].Journal of Cancer Research & Clinical Oncology,2017,143(8)：15631572.
[2] Torre LA,Freddie B,Siegel RL,et al. Global cancer statistics,2012 [J]. Ca：A Cancer Journal for Clinicians,2015,65(2)：87108.
[3] Peng G,Wang T,Yang KY,et al. A prospective,randomized study comparing outcomes and toxicities of intensitymodulated radiotherapy vs conventional twodimensional radiotherapy for the treatment of nasopharyngeal carcinoma [J]. Radiotherapy & Oncology,2012,104(3)：28693
[4] Liao JF,Ma L,Du XJ,et al. Prognostic value of cavernous sinus invasion in patients with nasopharyngeal carcinoma treated with intensitymodulated radiotherapy [J]. Plos One,2016,11(1)：e0146787.
[5] Chawalit L,Danita K,Anussara P,et al. Prognostic value of plasma EBV DNA for nasopharyngeal cancer patients during treatment with intensitymodulated radiation therapy and concurrent chemotherapy [J]. Radiol Oncol,2018,52(2)：195203.
[6] Wang TJC,Riaz N,Cheng SK,et al. Intensitymodulated radiation therapy for nasopharyngeal carcinoma：a review [J]. Journal of Radiation Oncology,2012,1(2)：129146.
[7] Lee AWM,Ma BBY,Waiton GN,et al. Management of nasopharyngeal carcinoma：current practice and future perspective[J].Journal of Clinical Oncology Official Journal of the American Society of Clinical Oncology,2015,33(29)：33563364.
[8] Zheng YJ,Han F,Xiao WW,et al. Analysis of late toxicity in nasopharyngeal carcinoma patients treated with intensity modulated radiation therapy [J]. Radiation Oncology,2015,10(1)：17.
[9] Lin YW,Chen CC,Lin LC,et al. The impact of reducedvolume,intensitymodulated radiation therapy on disease control in nasopharyngeal carcinoma [J]. Plos One,2015,10(4)：e0125283.
[10] Peng J,Lv BJ,Tang C,et al. Phase II trial of docetaxel combined with nedaplatin for patients with recurrent and metastatic nasopharyngeal carcinoma[J]. Drug Design Development & Therapy,2015,9(1)：64016405.
[11] 罗花南,马思敬,易春曦,等miR9过表达对鼻咽癌细胞迁移和侵袭的影响[J].陕西医学杂志,2017,46(10)：13321334.
[12] 王锋刚,王天昶,吴 磊,等淋巴结转移对鼻咽癌预后的研究[J].陕西医学杂志,2016,45(4):474477.
[13] Hsieh HCJ,Hsu LC,Hang SN,et al. Gemcitabine plus cisplatin for patients with recurrent or metastatic nasopharyngeal carcinoma in Taiwan：a multicenter prospective Phase II trial [J]. Japanese Journal of Clinical Oncology,2015,45(9)：819.
[14] Melling N,Grning A,Tachezy M,et al. Glasgow prognostic score may be a prognostic index for overall and perioperative survival in gastric cancer without perioperative treatment [J]. Surgery,2016,159(6)：154856.
[15] Xiao AZ,Xi YZCombined effects of genetic variants of the PTEN,AKT1,MDM2 and p53 genes on the risk of nasopharyngeal carcinoma [J]. Plos One,2014,9(3)：e92135

相似文献/References:

[1]苏建淳,张国义,卢秋霞,等.miR-124在鼻咽癌组织中的表达及其与预后关系研究*[J].陕西医学杂志,2020,49(2):144.
　SU Jianchun,ZHANG Guoyi,LU Qiuxia,et al.Expression of miR-124 in nasopharyngeal carcinoma and its relationship with prognosis[J].,2020,49(11):144.
[2]钟 亮,廖荣伟,刘清壮,等.调强适形放疗联合新辅助化疗治疗上下行型鼻咽癌疗效研究*[J].陕西医学杂志,2020,49(8):964.[doi:DOI:10.3969/j.issn.1000-7377.2020.08.013]
　ZHONG Liang,LIAO Rongwei,LIU Qingzhuang,et al.Effect of intensity-modulated radiotherapy combined with neoadjuvant chemotherapy in treatment of ascending and descending types of nasopharyngeal carcinoma[J].,2020,49(11):964.[doi:DOI:10.3969/j.issn.1000-7377.2020.08.013]
[3]易亭伍,梁 睿,宿向东.长链非编码RNA SNHG15通过miR-141-3p /KLF9机制调控鼻咽癌细胞增殖的实验研究[J].陕西医学杂志,2021,50(1):10.[doi:DOI:10.3969/j.issn.1000-7377.2021.01.003]
　YI Tingwu,LIANG Rui,SU Xiangdong.Study on long chain non-coding RNA SNHG15 regulating the proliferation of nasopharyngeal carcinoma cells through miR-141-3p/KLF9[J].,2021,50(11):10.[doi:DOI:10.3969/j.issn.1000-7377.2021.01.003]
[4]明 霞,刘 伟.血清叉头框D1在鼻咽癌患者中的表达及其与放疗后复发转移关系研究[J].陕西医学杂志,2024,(11):1495.[doi:DOI:10.3969/j.issn.1000-7377.2024.11.012]
　MING Xia,LIU Wei.Expression of serum FOXD1 in nasopharyngeal carcinoma patients and its relationship with recurrence and metastasis after radiotherapy[J].,2024,(11):1495.[doi:DOI:10.3969/j.issn.1000-7377.2024.11.012]

更新日期/Last Update: 2019-11-15